pubmed.ncbi.nlm.nih.gov

Current anti-vascular endothelial growth factor dosing regimens: benefits and burden - PubMed

Review

Current anti-vascular endothelial growth factor dosing regimens: benefits and burden

Julia A Haller. Ophthalmology. 2013 May.

Abstract

Topic: To examine the outcomes of clinical trials and case studies that investigated the different dosing regimens used for the 3 intravitreal anti-vascular endothelial growth factor (VEGF) inhibitors that are available currently. The Comparisons of Age-Related Macular Degeneration (AMD) Treatments Trial (CATT) data are discussed briefly here and are reviewed in greater detail in a separate accompanying article.

Clinical relevance: Sustained improvement with the 2 most widely used anti-VEGF drugs, bevacizumab and ranibizumab, requires monthly visits, posing a difficulty for patients. Thus, there is a need to evaluate whether individualized treatment regimens may reduce patient burden and improve patient outcomes.

Methods: Review of clinical trials and case studies presented at recent medical conferences and published in peer-reviewed literature.

Results: Numerous trials, including the Efficacy and Safety of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization (CNV) Secondary to AMD, Prospective Optical Coherence Tomography Imaging of Patients with Neovascular AMD Treated with Intraocular Ranibizumab, Study of Ranibizumab in Patients with Subfoveal CNV Secondary to AMD, Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with CNV Secondary to AMD or Macular Edema Secondary to Retinal Vein Occlusion, Safety Assessment of Intravitreal Lucentis for AMD, and CATT, have evaluated alternatives to monthly dosing. Evidence suggests that either a treat-as-needed or, possibly, a treat-and-extend regimen provides a reasonable approach to monthly injections recommended for bevacizumab and ranibizumab, with the caveat that as yet, careful and ongoing surveillance remains a key feature of optical management.

Conclusions: Individualization of antiangiogenic treatment using data from clinical trials evaluating various dosing regimens against the patient's disease, lifestyle, and economic restrictions continues to evolve.

PubMed Disclaimer

Cited by

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis.
Wang WJ, Chen J, Zhang XL, Yao M, Liu XY, Zhou Q, Qu YX. Wang WJ, et al. Int J Ophthalmol. 2015 Feb 18;8(1):138-47. doi: 10.3980/j.issn.2222-3959.2015.01.26. eCollection 2015. Int J Ophthalmol. 2015. PMID: 25709924 Free PMC article.
Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan.
Oluleye TS, Babalola YO, Majekodunmi O, Ijaduola M, Adewole AT. Oluleye TS, et al. Ann Afr Med. 2021 Oct-Dec;20(4):276-281. doi: 10.4103/aam.aam_61_20. Ann Afr Med. 2021. PMID: 34893565 Free PMC article.
Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y, Zhao M, Zhang C, Li S, Qi Y, Wang B, Huang L, Li X. Bai Y, et al. PLoS One. 2014 Nov 7;9(11):e112448. doi: 10.1371/journal.pone.0112448. eCollection 2014. PLoS One. 2014. PMID: 25380141 Free PMC article.
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy.
Hikichi T. Hikichi T. BMC Ophthalmol. 2015 Apr 10;15:37. doi: 10.1186/s12886-015-0026-y. BMC Ophthalmol. 2015. PMID: 25881324 Free PMC article.
Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions.
Guimaraes TAC, Georgiou M, Bainbridge JWB, Michaelides M. Guimaraes TAC, et al. Br J Ophthalmol. 2021 Feb;105(2):151-157. doi: 10.1136/bjophthalmol-2020-316195. Epub 2020 Apr 8. Br J Ophthalmol. 2021. PMID: 32269060 Free PMC article. Review.

Current anti-vascular endothelial growth factor dosing regimens: benefits and burden - PubMed